瑞马唑仑在肥胖患者围术期应用的进展

Advances in the Perioperative Use of Remimazolam in Obese Patients

摘要: 全球范围内，肥胖的患病率正以惊人的速度增长，已然成为一个严峻的公共卫生问题。根据世界卫生组织(WHO)的定义，体重指数(BMI) ≥ 30 kg/m²即为肥胖。肥胖不仅是脂肪的过度堆积，更与一系列严重的健康问题紧密相连，如心血管疾病、糖尿病、高血压以及某些癌症等。据统计，肥胖人群患心血管疾病的风险是非肥胖人群的2~3倍，患2型糖尿病的风险更是高达5~10倍。这不仅给患者的生活质量带来了极大的负面影响，也使他们在接受手术治疗时面临更高的风险和挑战。因此，如何精准地调整麻醉药物剂量，确保在肥胖患者体内达到理想的麻醉深度和效果，同时避免药物相关的不良反应，是麻醉医生面临的一大难题。

Abstract: Globally, the prevalence of obesity is increasing at an alarming rate, and it has become a serious public health problem. According to the World Health Organization (WHO), a body mass index (BMI) of ≥30 kg/m² is considered obese. Obesity is not only an excessive accumulation of fat, but also a series of serious health problems, such as cardiovascular disease, diabetes, high blood pressure and certain cancers. According to statistics, obese people have 2~3 times the risk of cardiovascular disease and 5~10 times the risk of type 2 diabetes. This not only has a significant negative impact on patients’ quality of life, but also exposes them to higher risks and challenges when undergoing surgery. Therefore, how to accurately adjust the dose of anesthetic drugs to ensure the ideal depth and effect of anesthesia in obese patients, while avoiding drug-related adverse reactions, is a major problem faced by anesthesiologists.